Hoth Therapeutics Executes Agreement to Assess the Effect of HT-003 Therapeutic Platform on Ulcerative Colitis and Crohn's Disease
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has partnered with REPROCELL Ltd. to evaluate the HT-003 therapeutic platform's effects on ulcerative colitis and Crohn's disease tissues. This collaboration aims to characterize therapies for inflammatory bowel diseases, which affect around 3 million adults in the U.S. The active ingredient in HT-003 shows anti-inflammatory properties targeting retinoic acid metabolism. Hoth is working on multiple studies to meet unmet patient needs in various indications.
- Collaboration with REPROCELL to enhance research on inflammatory bowel diseases.
- Focus on unmet patient needs, indicating potential market expansion.
- HT-003 demonstrates anti-inflammatory properties which may benefit IBD treatments.
- None.
NEW YORK, March 11, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed an agreement with REPROCELL Ltd., a contract research organization (CRO), providing a unique combination of products and services to power translational research, to assess the effect of the HT-003 therapeutic platform on tissue from ulcerative colitis and Crohn's disease patients. Fresh explants of ulcerative colitis and Crohn's disease tissues obtained from surgical resection will be used as the test systems to investigate the therapeutic potential of the HT-003 drugs via measurement of key biomarkers for these diseases. All testing will be performed by REPROCELL Ltd..
"This collaboration expands Hoth's efforts to characterize and develop therapies against inflammatory bowel diseases ("IBDs"), such as Crohn's disease and ulcerative colitis," stated Robb Knie, Chief Executive Officer of Hoth. "This is one of multiple studies being conducted on the anti-inflammatory properties of HT-003 and we expect these studies to allow us to accelerate finding solutions to unmet patient needs across multiple indications."
The active pharmaceutical ingredient of HT-003 has demonstrated anti-inflammatory properties and targets the retinoic acid metabolism pathway. Recent data in published literature suggests that aberrant retinoic acid regulation may contribute to the underlying inflammatory mechanism that causes IBD symptoms and restoring retinoic acid homeostasis may provide a potential therapeutic benefit. IBDs represent a large health burden in the United States, affecting approximately 3 million adults age 18 years and older that continues to increase each year. IBDs are characterized by an inflammation-mediated disease pathology as a result of an excessive mucosal adaptive and innate immune response within the gastrointestinal tract.
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused to improve the quality of life for patients suffering from indications including atopic dermatitis, skin toxicities associated with cancer therapy, chronic wounds, psoriasis, asthma, acne, mast-cell derived cancers & anaphylaxis and pneumonia. Hoth has also entered into two different agreements to further the development of two therapeutic prospects to prevent or treat COVID-19. To learn more, please visit https://ir.hoththerapeutics.com/.
About REPROCELL: REPROCELL is a contract research organization (CRO) that specializes in human tissue testing and iPSC research. They have worked with a range of clients, including 24 of the top 25 global Pharma companies, to better translate their discoveries into therapies. Areas of specialty include neurogenerative, bowel, skin, and respiratory diseases. REPROCELL is currently branching into the clinical space, with offerings in precision medicine and the generation of iPSCs for cell therapeutics. You can find out more at: https://www.reprocell.com/
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-executes-agreement-to-assess-the-effect-of-ht-003-therapeutic-platform-on-ulcerative-colitis-and-crohns-disease-301245610.html
SOURCE Hoth Therapeutics, Inc.
FAQ
What is the agreement between Hoth Therapeutics and REPROCELL about?
What diseases is the HT-003 platform targeting?
How many adults are affected by inflammatory bowel diseases in the U.S.?
What are the expected benefits of HT-003?
When was the agreement with REPROCELL announced?
